![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
双特异性抗体作为BCMACAR-T细胞疗法的桥梁,用于复发性/逆转性多发性髓瘤
David Fandrei1,2, Sabine Seiffert3, Michael Rade2
1Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany.
Blood cancer discovery
|October 23, 2024
概括
双特异性抗体 (BsAb) 作为有效的桥梁疗法 (BT) 在化学抗原受体T (CAR-T) 细胞治疗复发性/耐药性多发性髓瘤 (RRMM) 之前. 这种测序是安全和有效的,可以实现高响应率,并有可能改善CAR-T细胞功能.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 血液学 血液学 血液学
背景情况:
- 复发性/耐药性多发性骨髓瘤 (RRMM) 存在重大治疗挑战.
- 包括双特异性抗体 (BsAb) 和仿真抗原受体T (CAR-T) 细胞治疗在内的T细胞重定向疗法的最佳测序对于最大限度地提高患者的治疗结果至关重要.
研究的目的:
- 评估在RRMM患者的B细胞成熟前使用BsAb作为桥梁疗法 (BT) 的临床和免疫影响.
- 为了比较基于BsAb的BT与其他BT疗法的疗效和安全性.
主要方法:
- 在52名RRMM患者的临床和免疫学参数的纵向跟踪.
- 用BsAb作为BT,然后进行CAR-T细胞治疗.
- 在体外评估CAR-T细胞细胞毒性和单细胞免疫概况.
主要成果:
- 作为BT的BsAb实现了100%的整体响应率,明显高于其他BT方案 (46%).
- 在BsAb BT之后观察到不同的T细胞扩张模式 (早期CD4+CAR+,延迟CD8+CAR+) .
- 在BT组中,CAR-T细胞细胞毒性是可比的,但BsAb暴露与T细胞克隆性增加相关.
结论:
- 使用BsAb的桥梁疗法是RRMM中CAR-T细胞疗法之前的安全有效的策略.
- 这种测序方法可能会增强免疫反应,并对其他血液性恶性瘤具有潜在的适用性.
相关概念视频
01:27Tumor Immunotherapy
486
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
486
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:31Hybridoma Technology
14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K